Germany's federal disease control institute, contributing infectious disease surveillance, biological toxin standardisation, and pandemic preparedness expertise to European research consortia.
The Robert Koch-Institut is Germany's central federal institution for disease surveillance, prevention, and control. Within H2020, they contribute deep expertise in infectious disease epidemiology, biological threat detection, virus archiving, and pandemic preparedness. They develop standardised detection methods for biological toxins, maintain reference materials for laboratory proficiency testing, and support Europe-wide disease monitoring infrastructures. Their work bridges public health surveillance with applied biosecurity, making them a critical node in Europe's health emergency response architecture.
Core contributor across COMPARE (foodborne outbreak detection), I-MOVE+ (vaccine effectiveness monitoring), One Health EJP (zoonoses surveillance), PHIRI (population health data), and PANDEM-2 (pandemic response).
Coordinated EuroBioTox (EUR 2.1M), their largest project, establishing validated procedures for biological toxin identification including certified reference materials and proficiency testing.
Participated in both EVAg and EVA-GLOBAL, the European Virus Archive initiative providing virus collections and gold standard products to the research community.
Contributed to EVIDENT (Ebola correlates of protection), ECRAID-Plan (clinical research alliance planning), and PANDEM-2 (pandemic simulation and response tools).
Recent participation in PHINDaccess (omics data analysis for pathogen-host interaction) and VIROINF (linking virology with bioinformatics) signals growing computational biology capacity.
In the early H2020 period (2014–2018), RKI focused on traditional public health strengths: virus archiving, vaccine monitoring, foodborne outbreak detection, biological toxin standardisation, and One Health surveillance. From 2019 onward, a clear shift emerged toward computational and data-driven approaches — bioinformatics, omics, systems biology, population health data infrastructure, and pandemic simulation tools. This evolution reflects a move from primarily wet-lab and field epidemiology toward integrating digital health intelligence and preparedness planning.
RKI is increasingly investing in bioinformatics, health data infrastructure, and pandemic simulation — expect future projects at the intersection of computational epidemiology and public health response.
RKI operates almost exclusively as a participant (11 of 12 projects), contributing specialist public health expertise to large consortia rather than leading them. Their single coordinator role — EuroBioTox, by far their largest grant — was in their niche strength of biological toxin standardisation. With 189 unique partners across 40 countries, they are a well-connected hub that works broadly rather than repeatedly with the same groups, making them an accessible and experienced consortium partner.
RKI has collaborated with 189 distinct partners across 40 countries, giving them one of the broadest networks among European public health institutions in H2020. Their reach extends well beyond the EU, reflecting the global nature of infectious disease research and biosecurity.
RKI sits at the intersection of public health authority and research institution — they are not just studying diseases but actively responsible for Germany's national disease control. This dual mandate means they bring real-world operational context to EU projects that purely academic partners cannot. Their rare combination of biological threat detection expertise (EuroBioTox), virus biobanking (EVA-GLOBAL), and population health data infrastructure (PHIRI) makes them uniquely valuable for consortia needing credible, government-backed public health partners.
